Sanofi pulls the plug on two late-stage drugs
PARIS (Reuters) - Sanofi has stopped work on two drugs in late-stage development, iniparib and otamixaban, after tests showed both t...
Read More »PARIS (Reuters) - Sanofi has stopped work on two drugs in late-stage development, iniparib and otamixaban, after tests showed both t...
Read More »By Genevra Pittman NEW YORK (Reuters Health) - The number of New York parents who had their child skip at least one required vaccine...
Read More »
By Julie Steenhuysen CHICAGO (Reuters) - A Merck & Co drug designed to unmask tumor cells and mobilize the immune system into fighti...
Read More »By Julie Steenhuysen CHICAGO (Reuters) - A simple screening program for cervical cancer using vinegar and visual exams helped reduce...
Read More »By Bill Berkrot (Reuters) - Roche Holding AG's drug Avastin helped prolong the lives of women with advanced cervical cancer when add...
Read More »By Deena Beasley CHICAGO (Reuters) - Breast cancer is less likely to recur if women previously treated for the disease take the drug...
Read More »AMSTERDAM (Reuters) - Health authorities will cull 11,000 chickens at a farm in the Netherlands after an outbreak of a mild form of ...
Read More »By Deena Beasley CHICAGO (Reuters) - An experimental drug from Bristol-Myers Squibb shrank tumors in 31 percent of patients with adv...
Read More »By Deena Beasley CHICAGO (Reuters) - Data from a pivotal trial of Amgen Inc's experimental melanoma therapy shows that it improved s...
Read More »By Deena Beasley CHICAGO (Reuters) - A cancer drug sold by GlaxoSmithKline was shown in a clinical trial to extend by several months...
Read More »